CAJ | 학술논문

目的研究多西他赛联合卡培他滨二线治疗晚期食管鳞状细胞癌的疗效、患者不良反应、至疾病进展时间(TTP)和总生存(OS).方法 30例一线治疗失败的晚期食管鳞状细胞癌患者接受多西他赛60 mg/m2,第1天,静脉滴注1h;卡培他滨每天825 mg/m2,分2次口服,第1天至第14天;21d为1个周期,最多不超过6个周期.结果 30例患者接受中位2个周期(2～6个周期)化疗.中位随访时间15.4个月(3.0 ～ 31.5个月).疗效评价为部分缓解7例(23.3％),稳定13例(43.3％).中位TTP为3.0个月(95％CI 1.929 ～ 4.071),中位OS为8.3个月(95％CI 6.848 ～ 9.752).严重(3/4级)不良反应为中性粒细胞减少10例,贫血5例,血小板减少3例,手足综合征4例和疲乏3例.结论多西他赛联合卡培他滨对一线治疗失败的晚期食管鳞状细胞癌患者有效,不良反应可接受,可考虑作为治疗晚期食管鳞状细胞癌的二线化疗方案.
목적 연구다서타새연합잡배타빈이선치료만기식관린상세포암적료효、환자불량반응、지질병진전시간(TTP)화총생존(OS).방법 30례일선치료실패적만기식관린상세포암환자접수다서타새60 mg/m2,제1천,정맥적주1h;잡배타빈매천825 mg/m2,분2차구복,제1천지제14천;21d위1개주기,최다불초과6개주기.결과 30례환자접수중위2개주기(2～6개주기)화료.중위수방시간15.4개월(3.0 ～ 31.5개월).료효평개위부분완해7례(23.3％),은정13례(43.3％).중위TTP위3.0개월(95％CI 1.929 ～ 4.071),중위OS위8.3개월(95％CI 6.848 ～ 9.752).엄중(3/4급)불량반응위중성립세포감소10례,빈혈5례,혈소판감소3례,수족종합정4례화피핍3례.결론 다서타새연합잡배타빈대일선치료실패적만기식관린상세포암환자유효,불량반응가접수,가고필작위치료만기식관린상세포암적이선화료방안.
Objective To evaluate the effects of antitumor,toxicity and survival of second-line chemotherapy with docetaxel and capecitabine in patients with advanced esophageal squamous cell carcinoma.Methods Thirty eligible patients with measurable lesions received 1-hour intravenous treatment of docetaxel (60 mg/m2 on day 1) plus oral capecitabine (825 mg/m2 twice daily on days 1-14) every 3 weeks for up to 6 cycles.Results Patients received a median of two cycles of treatment (range 2-6).The median follow-up interview was 15.4 months (3.0-31.5 months).Intent-to-treat efficacy analysis demonstrated an overall response rate of 23.3 ％ (0 complete and 7 partial) and stability of 43.3 ％ (13 cases).The median time to progression was 3.0 months (95 ％ CI 1.929-4.071).The median survival was 8.3 months (95 ％ CI6.848-9.752).Severe adverse events (grade 3/4) reported were neutropenia (10 cases),anaemia (5 cases),thrombocytopenia (3 cases),hand-foot syndrome (4 cases),and fatigue (3 cases).Conclusion Docetaxel plus capecitabine have a manageable adverse event profile and promising activity in advance esophageal squamous cell carcinoma as a second-line treatment.